Quark Pharma snares $27M for RNAi work
Quark Pharmaceuticals has garnered $27 million in a new round of venture financing. The RNAi developer attracted the support of SBI Asset Management and SBI Investment, subsidiaries of the prestigious SBI Holding Inc.
"The additional funding we are announcing today will allow us to significantly expand our clinical program," says Quark CEO Daniel Zurr. "Between our licensee, Pfizer, and Quark, we anticipate having Quark drug candidates in five clinical programs by the second half of 2008."
- read the release
Related Articles:
NovaCardia, Quark Biotech file for $86M IPOs. Report
A billion-dollar lesson in RNAi economics. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
